Poly Medicure (531768) investor relations material

Executive summary

• Launched PolyMed 3.0 strategy to double revenue by FY 2030, focusing on high-tech, high-margin segments and global expansion.

• Achieved consolidated Q1 FY27 revenue of Rs 525.4 Cr, up 30.3% year-over-year, with strong domestic and international growth.

• Strengthened leadership with new CEO appointments for India/APAC, Brazil, and a new Head of Renal Business.

• Launched 6 new products in Q1 FY27 across Infusion Therapy and Critical Care.

• Unaudited standalone and consolidated financial results for the quarter ended 30 June 2026 were approved, with auditors expressing an unmodified review report.

Financial highlights

• Standalone Q1 revenue at INR 431 crore, up 12.3% year-over-year; domestic revenue grew 16.2%, international 10%.

• Consolidated Q1 revenue at INR 525 crore, up 30.3%; organic revenue up 12.4%.

• Standalone gross margin at 71.5%, consolidated gross margin at 73.4%, both up year-over-year.

• Standalone EBITDA margin at 28%, consolidated EBITDA margin at 24.1%; consolidated PAT at Rs 85.3 Cr.

• EPS (consolidated) at Rs 8.5, down 7.6% year-over-year.

Outlook and guidance

• Consolidated FY 2027 revenue guidance maintained at INR 2,300–2,400 crore, including full-year impact of acquisitions.

• Standalone revenue guidance at INR 1,900–2,000 crore; domestic business expected to grow over 20%, international over 15%.

• Standalone EBITDA margin expected at 25–27%; consolidated EBITDA margin at 23–25%.

• CapEx planned at INR 200–225 crore for FY 2027.

• Focus on expanding product portfolio, deepening clinical engagement, and scaling high-complexity verticals globally.